Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Aileron Therapeutics, Inc. (trading symbol: ALRN) on June 19, 2019. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes
No material financial changes were reported in this filing. The document details the outcomes of two specific shareholder votes:
- Director Election: Stockholders elected Nolan Sigal, M.D. as a Class II director for a three-year term ending in 2022.
- Auditor Ratification: Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the voting results for the election of Nolan Sigal, M.D. (13,935,730 votes For; 308,875 Withheld).
- Confirm the ratification of PricewaterhouseCoopers LLP as the independent auditor (18,061,010 votes For; 338,316 Against).
- Note the significant number of broker non-votes recorded for the director election (4,155,825).
- Review the company's status as an emerging growth company for potential differences in financial reporting standards.